

958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 11, 2012.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the

Federal Register on September 23, 1975, 40 FR 43745, all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: December 2, 2011.

Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011-31765 Filed 12-9-11; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated June 23, 2011, and published in the Federal Register on July 5, 2011, 76 FR 39123, Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Table with 2 columns: Drug and Schedule. Lists various controlled substances such as Cathinone (1235), Methcathinone (1237), Fenethylamine (1503), N-Ethylamphetamine (1475), N,N-Dimethylamphetamine (1480), Aminorex (1585), 4-Methylaminorex (1590), Gamma Hydroxybutyric Acid (2010), Methaqualone (2565), Mecloqualone (2572), 1-Pentyl-3-(1-naphthoyl)indole (7118), 1-Butyl-3-(1-naphthoyl)indole (7173), 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole (7200), Alpha-ethyltryptamine (7249), Ibogaine (7260), 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (7297), 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (7298), Lysergic acid diethylamide (7315), 2,5-Dimethoxy-4-(n-propylthiophenethylamine) (7348), Marihuana (7360), Tetrahydrocannabinols (7370), Parahexyl (7374), Mescaline (7381), 3,4,5-Trimethoxyamphetamine (7390), 4-Bromo-2,5-dimethoxyamphetamine (7391), 4-Bromo-2,5-dimethoxyphenethylamine (7392), 4-Methyl-2,5-dimethoxyamphetamine (7395), 2,5-Dimethoxyamphetamine (7396), 2,5-Dimethoxy-4-ethylamphetamine (7399), 3,4-Methylenedioxyamphetamine (7400), 5-Methoxy-3,4-methylenedioxyamphetamine (7401), N-Hydroxy-3,4-methylenedioxyamphetamine (7402), 3,4-Methylenedioxy-N-ethylamphetamine (7404), 3,4-Methylenedioxymethamphetamine (7405), 4-Methoxyamphetamine (7411), Peyote (7415), Alpha-methyltryptamine (7432), Bufotenine (7433), Diethyltryptamine (7434), Dimethyltryptamine (7435), Psilocybin (7437), Psilocyn (7438), 5-Methoxy-N,N-diisopropyltryptamine (7439), N-Ethyl-1-phenylcyclohexylamine (7455), 1-(1-Phenylcyclohexyl)pyrrolidine (7458), 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470), 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473), N-Ethyl-3-piperidyl benzilate (7482), N-Methyl-3-piperidyl benzilate (7484), N-Benzylpiperazine (7493), Acetyldihydrocodeine (9051).

Drug	Schedule
Benzylmorphine (9052)	
Codeine-N-Oxide (9053)	
Cyprenorphine (9054)	
Desomorphine (9055)	
Etorphine except HCl (9056)	
Codeine methylbromide (9070)	
Dihydromorphine (9145)	
Difenoxin (9168)	
Heroin (9200)	
Hydromorphenol (9301)	
Methyldesorphine (9302)	
Methyldihydromorphine (9304)	
Morphine methylbromide (9305)	
Morphine methylsulfonate (9306)	
Morphine-N-Oxide (9307)	
Myrophine (9308)	
Nicocodeine (9309)	
Nicomorphine (9312)	
Normorphine (9313)	
Pholcodine (9314)	
Thebacon (9315)	
Acetorphine (9319)	
Drotebanol (9335)	
Acetylmethadol (9601)	
Allylprodine (9602)	
Alphacetylmethadol except levo-alphacetylmethadol (9603)	
Alphameprodine (9604)	
Alphamethadol (9605)	
Benzethidine (9606)	
Betacetylmethadol (9607)	
Betameprodine (9608)	
Betamethadol (9609)	
Betaprodine (9611)	
Clonitazene (9612)	
Dextromoramide (9613)	
Diampromide (9615)	
Diethylthiambutene (9616)	
Dimenoxadol (9617)	
Dimepheptanol (9618)	
Dimethylthiambutene (9619)	
Dioxaphetyl butyrate (9621)	
Dipipanone (9622)	
Ethylmethylthiambutene (9623)	
Etonitazene (9624)	
Etoxidine (9625)	
Furethidine (9626)	
Hydroxypethidine (9627)	
Ketobemidone (9628)	
Levomoramide (9629)	
Levophenacymorphan (9631)	
Morpheridine (9632)	
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (9834)	
Noracymethadol (9633)	
Norlevorphanol (9634)	
Normethadone (9635)	
Norpipanone (9636)	
Phenadoxone (9637)	
Phenampromide (9638)	
Phenoperidine (9641)	
Piritramide (9642)	
Proheptazine (9643)	
Propoperidine (9644)	
Racemoramide (9645)	
Trimeperidine (9646)	
Phenomorphane (9647)	
Propiram (9649)	
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)	
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663)	
Tilidine (9750)	
Para-Fluorofentanyl (9812)	
3-Methylfentanyl (9813)	
Alpha-methylfentanyl (9814)	
Acetyl-alpha-methylfentanyl (9815)	

Drug	Schedule
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (9818)	I
Beta-hydroxyfentanyl (9830)	I
Beta-hydroxy-3-methylfentanyl (9831)	I
Alpha-methylthiofentanyl (9832)	I
3-Methylthiofentanyl (9833)	I
Thiofentanyl (9835)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Lisdexamfetamine (1205)	II
Phenmetrazine (1631)	II
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Glutethimide (2550)	II
Secobarbital (2315)	II
Nabilone (7379)	II
1-Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
4-Anilino-N-phenethyl-4-piperidine (8333)	II
Phenylacetone (8501)	II
1-Piperidinocyclohexanecarbonitrile (8603)	II
Alphaprodine (9010)	II
Anileridine (9020)	II
Coca Leaves (9040)	II
Cocaine (9041)	II
Codeine (9050)	II
Etorphine HCl (9059)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Diphenoxylate (9170)	II
Ecgonine (9180)	II
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Isomethadone (9226)	II
Meperidine (9230)	II
Meperidine intermediate-A (9232)	II
Meperidine intermediate-B (9233)	II
Meperidine intermediate-C (9234)	II
Metazocine (9240)	II
Methadone (9250)	II
Methadone intermediate (9254)	II
Metopon (9260)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	II
Thebaine (9333)	II
Dihydroetorphine (9334)	II
Opium, raw (9600)	II
Opium extracts (9610)	II
Opium fluid extract (9620)	II
Opium tincture (9630)	II
Powdered opium (9639)	II
Opium, granulated (9640)	II
Levo-alphaacetylmethadol (9648)	II
Opium poppy/Poppy Straw (9650)	II
Oxymorphone (9652)	II
Poppy Straw Concentrate (9670)	II
Phenazocine (9715)	II
Piminodine (9730)	II
Racemethorphan (9732)	II
Racemorphan (9733)	II
Alfentanil (9737)	II
Remifentanil (9739)	II
Sufentanil (9740)	II
Carfentanil (9743)	II
Tapentadol (9780)	II
Bezitramide (9800)	II
Fentanyl (9801)	II
Moramide-intermediate (9802)	II

The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.

Comments and requests for hearings on applications to import narcotic raw material are not appropriate, 72 FR 3417 (2007). Regarding all other basic classes of controlled substances, no comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Research Triangle Institute to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Research Triangle Institute to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: December 5, 2011.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011-31767 Filed 12-9-11; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 15, 2011, Johnson Matthey Pharma Services, 70 Flagship Drive, North Andover, Massachusetts 01845, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100)	II
Methylphenidate (1724)	II
Hydrocodone (9193)	II

The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company's primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company's customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than February 10, 2012.

Dated: December 5, 2011.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011-31771 Filed 12-9-11; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated August 10, 2011, and published in the **Federal Register** on August 18, 2011, 76 FR 51400, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II.

The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambridge Isotope Lab to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Cambridge Isotope Lab to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the

company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: December 5, 2011.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011-31774 Filed 12-9-11; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances Notice of Registration

By Notice dated August 10, 2011, and published in the **Federal Register** on August 18, 2011, 76 FR 51401, Chemica, 316 West 130th Street, Los Angeles, California 90061, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Methamphetamine (1105), a basic class of controlled substance listed in schedule II.

The above listed controlled substance is an intermediate in the manufacture of Benzphetamine, a schedule III non-narcotic controlled substance. The company plans to utilize a bulk active pharmaceutical ingredient (API) as an intermediate for the development of another controlled substance, and further distribution to its customers. The methamphetamine will not be sold as a commercial product.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Chemica to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Chemica to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.